Prostaglandin-mediated hypercalcemia: a paraneoplastic syndrome.
Evidence has been presented for prostaglandin-mediated hypercalcemia and bone resorption in malignancies of both, experimental animals and man. Occurence of hypercalcemia in cancer patients is known for a long time, but its pathogenesis has been poorly understood so far. Besides ectopic parathyroid hormone secretion by tumors, an osteoclast-activating factor released from leukocytes and direct bone destruction by tumor cells, prostaglandins of the E series have to be considered as one of the candicates involved in the pathomechanism of hypercalcemia and osteoclastic osteolysis in cancer patients. This new concept on the pathophysiology of cancer-associated hypercalcemia has implications for the diagnosis and management of this common complication of neoplastic disease.
D000818:Animals; D001862:Bone Resorption / Q000209:etiology; D002294:Carcinoma, Squamous Cell / Q000209:etiology; D000242:Cyclic AMP / Q000032:analysis; D005354:Fibrosarcoma / Q000150:complications; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology*; D007680:Kidney Neoplasms / Q000209:etiology; D008175:Lung Neoplasms / Q000209:etiology; D051379:Mice; D009369:Neoplasms / Q000378:metabolism; D009384:Paraneoplastic Endocrine Syndromes; D010281:Parathyroid Hormone / Q000378:metabolism; D011449:Prostaglandin Endoperoxides / Q000378:metabolism; D011453:Prostaglandins / Q000009:adverse effects*
D010281:Parathyroid Hormone; D011449:Prostaglandin Endoperoxides; D011453:Prostaglandins; D000242:Cyclic AMP